[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100553251":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":33,"centralContacts":34,"locations":44,"responsibleParty":58,"collaborators":33,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":65,"acronym":33,"eligibilityCriteria":66,"healthyVolunteers":67,"sex":68,"minAge":69,"maxAge":70,"enrollmentInfo":71,"targetDuration":33,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":33,"overallStatus":46,"whyStopped":33,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Brigham and Women's Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Medication","ACTIVE_COMPARATOR","one group will receive Oxytocin infusion: 30 IU in 500 ml of 0.9% normal saline .",[13],"Drug: Oxytocin",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","one group will receive 500 ml of 0.9% normal saline",[19],"Drug: Placebo",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Oxytocin","Intravenous Oxytocin infusion",[9],[27],"Pitocin",{"type":22,"name":15,"description":29,"armGroupLabels":30,"otherNames":31},"0.9% Saline",[15],[32,29],"Normal Saline",null,[35,40],{"name":36,"role":37,"phone":38,"phoneExt":33,"email":39},"John J. Kowalczyk, MD","CONTACT","617-732-8220","jkowalczyk@bwh.harvard.edu",{"name":41,"role":37,"phone":42,"phoneExt":33,"email":43},"Rusul I Al-Ani","617-525-6483","rual-ani@bwh.harvard.edu",[45],{"facility":5,"status":46,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":33},"RECRUITING","Boston","Massachusetts","02215","United States","US",{"type":53,"coordinates":54},"Point",[55,56],-71.05977,42.35843,{"lat":56,"lon":55},{"type":59,"investigatorFullName":36,"investigatorTitle":60,"investigatorAffiliation":5,"oldNameTitle":33,"oldOrganization":33},"PRINCIPAL_INVESTIGATOR","Director of Fellowship Research","100553251","phase-2-intravenous-oxytocin-for-post-operative-pain-after-minimally-invasive-hysterectomy-100553251",false,"NCT06483659","Intravenous Oxytocin for Post Operative Pain After Minimally Invasive Hysterectomy","Inclusion Criteria:\n\n* Ages 18-65 years old\n* ASA category 1-3\n* Scheduled to undergo minimally invasive hysterectomy\n* No documented allergy to oxytocin\n\nExclusion Criteria:\n\n* American Society of Anesthesiologists (ASA) group 4 or greater\n* Age \\>65 years old\n* Additional surgical procedures including but not limited to minor laparotomy, omentectomy, cystectomy, vaginectomy, and\u002For ablation of endometriosis.\n* Active opioid prescription of the equivalent of oxycodone \\>10 mg \u002Fday\n* Opioid use disorder, including patients in treatment receiving naltrexone or Suboxone (Buprenorphine-naloxone)\n* Allergies to any study medication: acetaminophen, celecoxib, ketorolac, fentanyl, hydromorphone, or oxycodone.\n* Epidural\u002FRegional anesthesia for intra-operative or post-operative pain.\n* Inability to understand the questionnaires\n* Intra-operative and post-operative exclusion: Procedure converted to open or extension of primary surgery, Intra-operative EBL \\>500 ml., Placement of epidural catheter or regional anesthesia at PACU for pain management, Hospitalization of the patient due to surgical or anesthetic complications",true,"FEMALE","18 Years","65 Years",{"count":72,"type":73},152,"ESTIMATED","INTERVENTIONAL",[76],"PHASE2","This is a randomized, double-blinded, placebo-controlled trial to compare the effectiveness of IV oxytocin infusion to placebo on peri-operative opioid consumption and reducing post-operative pain following a minimally invasive hysterectomy under general anesthesia.",[79],"Postoperative Pain","2026-08-11",{"date":82,"type":83},"2026-08-13","ACTUAL",{"date":85,"type":83},"2025-06-01",{"date":87,"type":73},"2028-06-30",{"name":5,"class":6},1]